Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

• Главные авторы: Desirée Van Oorschot (Автор), Anastassia Anastassopoulou (Автор), Barbara Poulsen Nautrup (Автор), Lijoy Varghese (Автор), Alfred von Krempelhuber (Автор), Mohamed Neine (Автор), Stéphane Lorenc (Автор), Desmond Curran (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...